Ahmed Bouzidi

Ahmed is Vice-President Biotech of ProductLife Group, a Global Life Science Consultancy company providing assistance to biopharmaceutical companies through all phases of product development, market access and post-marketing. He is also Senior Associate of the Royal Society of Medicine (London). Until recently, Ahmed was founder & CEO of Vaxeal Holding SA, biotech SME specialized in Immuno-Oncology (pre-IPO stage), President of the European Biopharmaceutical Enterprises (Brussels), the leading European Trade Association representing biopharmaceutical companies from innovative SMEs to worldwide leaders, and board member of Vaccines Europe. He previously founded and managed SEDAC-Therapeutics inc., a leading biotech pioneer in peptide-based immunotherapies (spin-off of Pasteur Institute and CNRS), and Biophysiomics inc. (acquired by Kuachang Science & Technology, China). He held senior advisory positions with high-level US & Chinese healthcare stakeholders (Public & Private Institutions), and he worked for 10 years as Senior Researcher in the biotech department of the LFB (France). He is the author of more than 40 peer-reviewed publications and inventor of 14 patents. Ahmed holds a PhD in Cellular Biology and an MBA (University of New Hampshire, Durham, US). His executive management experience in the biotechnology industries spans more than 25 years.